Circ_CHFR Promotes Platelet-Derived Growth Factor-BB-Induced Proliferation, Invasion, and Migration in Vascular Smooth Muscle Cells Via the MiR-149-5p/NRP2 Axis
Overview
Affiliations
Circular RNA checkpoint with forkhead and ring finger domains (circ_CHFR) were reported to regulate vascular smooth muscle cell (VSMC) dysfunction during atherosclerosis (AS). However, the molecule mechanism of circ_CHFR in AS remains largely unclear. Human VSMCs (HVSMCs) were exposed to platelet-derived growth factor-BB (PDGF-BB) in vitro. Levels of circ_CHFR, microRNA (miR)-149-5p, and neuropilin 2 (NRP2) were determined using quantitative real-time polymerase chain reaction and western blot. Cell proliferation, migration, and invasion were analyzed using cell counting kit-8, colony formation, flow cytometry, wound healing, and transwell assays. The binding interaction between miR-149-5p and circ_CHFR or NRP2 was investigated using the dual-luciferase reporter and RNA immunoprecipitation assays. Circ_CHFR was elevated in PDGF-BB-induced HVSMCs in a dose-independent manner. Silencing of circ_CHFR reversed PDGF-BB-evoked promotion of cell proliferation, migration and invasion, as well as suppression of cell apoptosis in HVSMCs. Mechanistically, circ_CHFR directly bound to miR-149-5p, and miR-149-5p inhibition attenuated the effects of circ_CHFR knockdown on PDGF-BB-induced HVSMCs. Besides, NRP2 was confirmed to be a target of miR-149-5p, and circ_CHFR could regulate NRP2 expression through sponging miR-149-5p. Moreover, miR-149-5p overexpression abolished PDGF-BB-triggered enhancement of cell proliferation, migration, and invasion by targeting NRP2. Circ_CHFR promoted the proliferation, invasion, and migration of PDGF-BB-induced HVSMCs through miR-149-5p/NRP2 axis, providing a new insight into the pathogenesis of AS and a potential therapeutic target for AS treatment.
Ma S, Qian H, Zhou Q, Lei C Cardiovasc Toxicol. 2024; 24(10):1077-1089.
PMID: 39126580 DOI: 10.1007/s12012-024-09899-6.
Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach.
Fularski P, Czarnik W, Dabek B, Lisinska W, Radzioch E, Witkowska A Int J Mol Sci. 2024; 25(10).
PMID: 38791250 PMC: 11121693. DOI: 10.3390/ijms25105212.
Ang-1 and VEGF: central regulators of angiogenesis.
Zhao Y, Yu B, Wang Y, Tan S, Xu Q, Wang Z Mol Cell Biochem. 2024; 480(2):621-637.
PMID: 38652215 DOI: 10.1007/s11010-024-05010-3.
Wang L, Li H, Zheng Z, Li Y Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(2):1093-1104.
PMID: 37606757 DOI: 10.1007/s00210-023-02663-7.
Circular RNA as Therapeutic Targets in Atherosclerosis: Are We Running in Circles?.
Triska J, Mathew C, Zhao Y, Chen Y, Birnbaum Y J Clin Med. 2023; 12(13).
PMID: 37445481 PMC: 10342353. DOI: 10.3390/jcm12134446.